Baker Bros. Advisors 13F: New $33M Stake in Aktis Oncology (AKTS)

Baker Bros. Advisors initiated a brand-new position in Aktis Oncology, Inc. (NasdaqGS: AKTS), purchasing 996,351 shares during the first quarter of 2026. The newly acquired stake was valued at approximately $32.71 million, according to the fund's latest Form 13F filing with the Securities and Exchange Commission. Because 13F filings are backward-looking and reflect holdings as of March 31, 2026, they do not necessarily represent the fund's current investment portfolio.

Baker Bros. Builds a Brand-New Stake in Aktis

Baker Bros. Advisors chose to open a new position in the biotechnology firm, acquiring 996,351 shares. With a reported cost basis of $20.20 per share, the fund's total investment in Aktis Oncology reached a value of $32,710,205. This represents a significant initial commitment to the clinical-stage oncology developer as the firm advances its radiopharmaceutical pipeline.

Other Big Funds Are Buying Aktis Too

This fresh position from Baker Bros. Advisors follows a broader trend of institutional accumulation in Aktis Oncology during the same period. Earlier filings revealed that RTW Investments also established a major foothold in the stock. RTW Investments opened a new position by purchasing 1.59 million shares, a stake valued at approximately $34.9 million. These parallel moves by prominent healthcare investors show growing institutional appetite for the biotech firm's cancer-targeting technology.

Aktis Stock Climbs Near 52-Week Highs

On Sunday, shares of Aktis Oncology traded at $32.83. The stock has shown strong upward momentum, trading well above its 50-day moving average of $24.33 and its 200-day moving average of $21.60. This price action places the stock near the upper end of its 52-week trading range of $14.72 to $34.19. With a market capitalization of $1.19 billion, Aktis has captured investor attention as its share price moves toward its peak.

Recent Earnings and Financial Health

Aktis Oncology reported revenue of $10.06 million, reflecting a strong revenue growth rate of 1.114. As is common with clinical-stage biotechnology firms investing heavily in research and development, the company is not yet profitable and has a negative forward P/E ratio of -9.978302. Its earnings per share stand at -$1.32. However, the company maintains a highly liquid balance sheet, boasting a current ratio of 16.327 and a quick ratio of 16.173, alongside a very low debt-to-equity ratio of 2.318. Aktis Oncology is scheduled to report its next quarterly earnings on November 12, 2026.

Wall Street Analysts Cheer Aktis Oncology's Pipeline

Several research firms have recently shared positive views on the stock. On October 2, 2026, Wedbush reiterated its Outperform rating on Aktis Oncology with a price target of $35.00. Oppenheimer initiated coverage on September 9, 2026, with an Outperform rating and a $40.00 price target. BMO Capital also started coverage on August 19, 2026, assigning an Outperform rating and a $37.00 price target. Additionally, JP Morgan maintained an Overweight rating on July 14, 2026, and raised its target from $30.00 to $33.00. Overall, eight analysts follow the stock, establishing a consensus mean price target of $34.81.

What Is Aktis Oncology?

Aktis Oncology is a Boston-based biotechnology company focused on developing targeted radiopharmaceuticals to treat solid tumors. Its lead program is in early-stage clinical trials to treat various cancers, including breast and lung cancers. The company has strategic development agreements with major industry players like Eli Lilly, supporting its efforts to bring novel therapies to market.

What to Watch at Aktis Oncology, Inc.

Investors will want to keep a close eye on the company's next earnings release on November 12, 2026, for updates on its clinical trial progress and cash burn rate. Future institutional filings will also reveal whether Baker Bros. Advisors or other major healthcare funds continue to expand their holdings. Because 13F filings are delayed by up to 45 days after the end of a quarter, they should be viewed as a historical snapshot rather than a real-time indicator of fund activity.